Drugs / ALXN1910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05307978 | Apr 2022 → Feb 2023 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN1910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05307978 ↗ |
| Route | Subcutaneous | “ALXN1910 SC” NCT05307978 ↗ |